

Supplementary Material 1. External link for English and Korean version of Kidney Disease Quality of Life Short Form (KDQOL-SFTM), version 1.3.

- 1) English version: <https://www.rand.org/content/dam/rand/pubs/papers/2006/P7994.pdf>
- 2) Korean version: https://www.rand.org/content/dam/rand/www/external/health/surveys_t

Supplementary Table 1. Baseline characteristics according to physical and mental health status

| Variable | Overall (n = 568) | Physical health status | | P value | Mental health status | | P value |
|----------------------------|----------------------|--------------------------|---------------------------|---------|--------------------------|---------------------------|---------|
| | | Lower group (n = 284) | Higher group (n = 284) | | Lower group (n = 284) | Higher group (n = 284) | |
| Smoking | | | | 0.353 | | | 0.587 |
| Never-smoker | 294 (51.8) | 154 (54.2) | 140 (49.3) | | 142 (50.0) | 152 (53.5) | |
| Current smoker | 70 (12.3) | 30 (10.6) | 40 (14.1) | | 38 (13.4) | 32 (11.3) | |
| Ex-smoker | 200 (35.2) | 97 (34.2) | 103 (36.3) | | 102 (35.9) | 98 (34.5) | |
| Unknown | 4 (0.7) | 3 (1.1) | 1 (0.4) | | 1 (0.4) | 2 (0.7) | |
| Glucose (mg/dL) | 153.7 ± 82.6 | 156.3 ± 81.0 | 151.2 ± 84.1 | 0.460 | 159.4 ± 85.6 | 148.0 ± 79.2 | 0.103 |
| HbA1c (%) | 6.2 ± 1.5 | 6.3 ± 1.6 | 6.1 ± 1.4 | 0.055 | 6.2 ± 1.6 | 6.2 ± 1.5 | 0.699 |
| Total cholesterol (mg/dL) | 155.6 ± 50.0 | 155.8 ± 49.9 | 155.5 ± 50.2 | 0.944 | 158.1 ± 50.9 | 153.2 ± 48.9 | 0.266 |
| Single-pool Kt/V (n = 436) | 1.37 ± 0.51 | 1.40 ± 0.53 | 1.34 ± 0.49 | 0.231 | 1.33 ± 0.42 | 1.40 ± 0.59 | 0.135 |
| URR (%; n = 436) | 66.7 ± 9.5 | 67.1 ± 10.0 | 65.3 ± 9.0 | 0.389 | 66.0 ± 9.9 | 67.6 ± 9.06 | 0.067 |
| Iron (µg/dL; n = 532) | 64.2 ± 41.8 | 62.8 ± 43.1 | 65.6 ± 40.5 | 0.445 | 64.3 ± 40.4 | 64.2 ± 43.3 | 0.964 |
| Ferritin (ng/mL; n = 506) | 243.0 ± 251.9 | 256.6 ± 260.5 | 229.2 ± 242.6 | 0.222 | 231.3 ± 222.4 | 255.1 ± 279.3 | 0.094 |
| ESA use | | | | 0.800 | | | 0.694 |
| Epoetin alpha/beta | 284 (50.0) | 148/10 (52.1/3.5) | 136/14 (47.9/4.9) | | 139/15 (48.9/5.3) | 145/9 (51.1/3.2) | |
| Epoetin beta | 24 (4.2) | 10 (3.5) | 14 (4.9) | | 15 (5.3) | 9 (3.2) | |
| Darbepoietin alpha | 166 (29.2) | 79 (27.8) | 87 (30.6) | | 80 (28.2) | 86 (30.3) | |
| CERA | 13 (2.3) | 7 (2.5) | 6 (2.1) | | 7 (2.5) | 6 (2.1) | |
| Not use | 81 (14.3) | 40 (14.1) | 41 (14.4) | | 43 (15.1) | 38 (13.4) | |
| ESA dose | | | | | | | |
| Epoetin alpha/beta (IU/wk) | 10,418 ± 4,056 | 10,809 ± 4,132 | 10,007 ± 3,944 | 0.084 | 10,935 ± 4,148 | 9,902 ± 3,906 | 0.026 |
| Darbepoietin alpha (µg/wk) | 45 ± 26 | 45 ± 33 | 45 ± 18 | 0.813 | 49 ± 34 | 41 ± 15 | 0.065 |
| CERA (µg/mo) | 129 ± 77 | 148 ± 77 | 108 ± 78 | 0.371 | 134 ± 90 | 123 ± 67 | 0.811 |

CERA, continuous erythropoietin receptor activator; ESA, erythropoiesis-stimulating agent; HbA1C, hemoglobin A1c; URR, urea reduction rate.

Physical and mental health status was classified by upper and lower half of physical and mental health composite scores.